Author information unavailable
Abstract
In a trial including 198 patients in whom several lines of treatments had failed, pasireotide normalised IGF-1 and GH levels and sometimes reduced the size of the pituitary adenoma, but often at a cost of developing diabetes.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In a trial including 198 patients in whom several lines of treatments had failed, pasireotide normalised IGF-1 and GH levels and sometimes reduced the size of the pituitary adenoma, but often at a cost of developing diabetes.
Key concepts: Acromegaly, Pasireotide, Pegvisomant, Medicine, Pituitary adenoma, Internal medicine, Diabetes mellitus, Endocrinology